PRA Health Sciences

PRA Health Sciences is a contract research organization (CRO) with headquarters in Raleigh, North Carolina that was founded as the Anti-Inflammatory Drug Study Group in 1976, renamed PRA in 1982, as it expanded into other therapeutic areas besides inflammation.[2]

PRA Health Sciences
TypeSubsidiary
Nasdaq: PRAH
IndustryPharmaceuticals & Biotechnology
Founded1976 (1976)
Charlottesville, Virginia, U.S.
Headquarters
Raleigh, North Carolina
,
U.S.
Area served
Worldwide
Key people
Colin Shannon (President and CEO)
Revenue
  • US$ 1.948 billion (2017)[1]
  • US$ 1.580 billion (2016) [1]
Number of employees
17,000+[1]
ParentICON plc
Websiteprahs.com

Background

In 2013 the company was acquired by Kohlberg Kravis Roberts, which brought the company public in November 2014 and maintained shares until September 2019.[3]

In August 2017, the company acquired Conshohocken-based real-world healthcare data, analytics, and technology solutions company Symphony Health for US$530 million.[4]

PRA's 2018 revenue was US$2.87 billion.[5]

PRA was acquired by ICON on 1 July 2021.[6]

References
  1. "PRA 10-K For the fiscal year ended December 31, 2017". PRA Health Sciences via SEC Edgar. 2018-02-02. See SEC Edgar index page for PRA for updates
  2. "PRA Health Sciences becomes latest big CRO to launch IPO". CenterWatch News Online. 13 November 2014.
  3. "PRA Health Sciences Announces Secondary Offering and Concurrent Share Repurchase". Globenewswire. September 3, 2019.
  4. Liu, Angus (August 8, 2017). "PRA Health Sciences makes $530M Symphony buy, reports 16% revenue growth in Q2". FierceBiotech.
  5. "Investors | ICON PLC".
  6. "ICON acquisition creates world-leading healthcare intelligence and clinical research organisation". 1 July 2021.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.